{"title":"利妥昔单抗治疗Baló同心性硬化症:一项长期随访的病例研究","authors":"Lina Okar , Beatriz Canibano , Dirk Deleu","doi":"10.1016/j.nerep.2023.100177","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>: Baló concentric sclerosis (BCS) is a rare demyelinating disorder that overlaps with other demyelinating diseases. BCS usually present in the context of multiple sclerosis (MS) or preceding typical MS. It rarely presents as an isolated lesion, . IV methyl prednisolone (IVMP) is the mainstay in the treatment with various outcomes. Maintenance therapy is still not clearly defined.</p><p>Case presentation/case report: We present a case of isolated BCS that responded clinically and radiologically to long-term rituximab therapy.</p></div><div><h3>Conclusion</h3><p>: A definite guideline for treating patient with BCS either with MS or as isolated entity is still controversial. Our case reflects a remarkable response to rituximab in achieving clinical and radiological long-term remission.</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"4 ","pages":"Article 100177"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Management of Baló Concentric Sclerosis with rituximab: A case study with long-term follow-up\",\"authors\":\"Lina Okar , Beatriz Canibano , Dirk Deleu\",\"doi\":\"10.1016/j.nerep.2023.100177\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>: Baló concentric sclerosis (BCS) is a rare demyelinating disorder that overlaps with other demyelinating diseases. BCS usually present in the context of multiple sclerosis (MS) or preceding typical MS. It rarely presents as an isolated lesion, . IV methyl prednisolone (IVMP) is the mainstay in the treatment with various outcomes. Maintenance therapy is still not clearly defined.</p><p>Case presentation/case report: We present a case of isolated BCS that responded clinically and radiologically to long-term rituximab therapy.</p></div><div><h3>Conclusion</h3><p>: A definite guideline for treating patient with BCS either with MS or as isolated entity is still controversial. Our case reflects a remarkable response to rituximab in achieving clinical and radiological long-term remission.</p></div>\",\"PeriodicalId\":100950,\"journal\":{\"name\":\"Neuroimmunology Reports\",\"volume\":\"4 \",\"pages\":\"Article 100177\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuroimmunology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667257X23000153\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroimmunology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667257X23000153","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Management of Baló Concentric Sclerosis with rituximab: A case study with long-term follow-up
Background
: Baló concentric sclerosis (BCS) is a rare demyelinating disorder that overlaps with other demyelinating diseases. BCS usually present in the context of multiple sclerosis (MS) or preceding typical MS. It rarely presents as an isolated lesion, . IV methyl prednisolone (IVMP) is the mainstay in the treatment with various outcomes. Maintenance therapy is still not clearly defined.
Case presentation/case report: We present a case of isolated BCS that responded clinically and radiologically to long-term rituximab therapy.
Conclusion
: A definite guideline for treating patient with BCS either with MS or as isolated entity is still controversial. Our case reflects a remarkable response to rituximab in achieving clinical and radiological long-term remission.